Coastlands Capital LP purchased $65K of ADIL (indirect holdings)
Coastlands Capital LP purchased 25,000 indirectly-held shares of ADIAL PHARMACEUTICALS, INC. (ADIL) at $2.60 on 2026-06-29.
How this was made
The 30-second read
Why it matters
A 10% owner’s indirect open-market buy of 25,000 shares at $2.60 is newly disclosed, but it does not include any new company-specific operating catalyst.
Market read
Traders may treat the filing as a small sentiment/positioning signal, but it is unlikely to drive a major repricing without additional fundamental news.
What to watch
No follow-on guidance, trial results, or financing terms are disclosed; traders may over-weight small Form 4 activity versus fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for ADIAL PHARMACEUTICALS, INC. (ADIL).
Ticker impact
Coastlands Capital LP, a 10% owner, filed a Form 4 open-market purchase of 25,000 ADIL shares at $2.60 on 2026-06-29.
Likely limited, short-lived sentiment lift; no clear directional catalyst beyond positioning.
Form 4 provides a fresh, primary-source transaction, yet it is an indirect holding by a 10% owner with a relatively small dollar value ($65k) and no accompanying operational/regulatory update.
Market effects
No sector read-across; this is a single-company ownership transaction with no new clinical/regulatory datapoints.
None indicated.
None indicated.
Counterpoint
The purchase may reflect routine portfolio rebalancing or liquidity needs rather than a new bullish thesis, especially given the indirect nature and lack of a 10b5-1 plan.
Key entities
- issuerADIAL PHARMACEUTICALS, INC.
Subject of the Form 4 insider transaction; received disclosure of an indirect open-market purchase by a 10% owner.
- 10% ownerCoastlands Capital LP
Reporter of the Form 4; purchased 25,000 shares indirectly at $2.60/share on 2026-06-29.